The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

The Motley Fool. DATE Wednesday, July 16, 2025 at 8:30 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — ...

Q2 2025 Earnings Call Transcript July 16, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of developing psoriatic arthritis, an inflammatory condition that impacts the ...

Self-care methods for psoriatic arthritis (PsA) include staying active with gentle exercises, getting enough sleep, and ...

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Senior medical experts have explained why women are more at risk of developing arthritis than men, attributing it to several factors, including hormonal ...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. "Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating ...

A new groundbreaking study by researchers from University of Birmingham, UCL, Great Ormond Street Hospital and Birmingham Children's Hospital has revealed important clues into what is driving ...